Aripiprazole augmentation early in treatment is useful for inducing response in major depressive disorder, although caution should be exercised when increasing the dose to >6 mg/day, a study has shown.
The levels of depression biomarkers in healthy postmenopausal women were lower after 8 weeks of increased daily physical activity, suggesting that the intervention may prevent depression in older people.
Individuals with depressive symptoms are at high risk of a first hospitalization for heart failure (HF) with preserved ejection fraction but not for HF with reduced ejection fraction, according to a study.
Treatment with cariprazine for patients with bipolar I depression is effective, well tolerated and relatively safe in adults with bipolar I depression in improving depressive symptoms, according to the results of a phase III study.
Specific metabolic parameters such as waist circumference and C-reactive protein are elevated, whereas high-density lipoprotein (HDL) cholesterol levels are reduced in the presence of high levels of depression and perceived stress, a study has reported.
New drug applications approved by US FDA as of 01 - 15 March 2019 which includes New Molecular Entities (NMEs) and new biologics. It
does not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.